NORTHAMPTON, MA / ACCESS Newswire / April 1, 2025 / In 2006, Tomas Cihlar knew all too well that despite initial successes ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...

LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...